13 completed, 4 recruiting, 4 unknown, 3 not yet recruiting. 26 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 13, Recruiting 4, Unknown 4, Not yet recruiting 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Squamous Intraepithelial Lesions: new trials by email Literature Review of Squamous Intraepithelial Lesions trials Research Report on Squamous Intraepithelial Lesions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA) - HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2026-09-04 | 2026-10-29 |
| Evaluation of NWRD09 for HPV-16 Related Cervical HSIL NWRD09 Injection, NWRD09 Placebo - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Not yet recruiting | Newish Biotech (Wuxi) Co., Ltd. | 156 | 2026-08-01 | 2026-07-17 |
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination - Cervical Intraepithelial Neoplasia, Papillomavirus Infections | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 230 | 2026-07-01 | 2026-07-09 |
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities EGCG and Quinine Sulfate Vaginal Suppository, Placebo - High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion | Phase 2 | Recruiting | Amplexd Therapeutics, Inc. | 45 | 2026-04-30 | 2026-05-14 |
| Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV Nonavalent HPV vaccine (9vHPV) - HPV, High-risk HPV (Any Strain) | Phase 2 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | 80 | 2026-02-01 | 2026-02-11 |
| Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL NWRD08 administered by electroporation, Placebo administered by electroporation - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Recruiting | Newish Biotech (Wuxi) Co., Ltd. | 150 | 2025-11-11 | 2026-02-17 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Aminolevulinic acid hydrochloride 10% topical gel with Red Light - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | The Center for Clinical and Cosmetic Research | 20 | 2024-08-14 | 2024-08-29 |
| Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial 85%TCA topical application, 3% acetic acid - Cervical Intraepithelial Neoplasia, Trichloroacetic Acid | Phase 2 | Unknown | Department of Medical Services Ministry of Public Health of Thailand | 44 | 2024-08-01 | 2024-11-14 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Aminolevulinic Acid 20% Topical Solution with Blue Light - Facial Cutaneous Squamous Cell Carcinoma in Situ | Phase 2 | Completed | The Center for Clinical and Cosmetic Research | 32 | 2023-08-08 | 2025-02-12 |
| 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream - Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ | Phase 2 / Phase 3 | Recruiting | Boston University | 200 | 2022-10-15 | 2025-11-28 |
| A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC STP705, Placebo Saline - Squamous Cell Carcinoma in Situ | Phase 2 | Completed | Sirnaomics | 44 | 2021-05-18 | 2024-03-18 |
| VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis - Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia | Phase 2 | Completed | AIDS Malignancy Consortium | 44 | 2018-09-21 | 2026-07-08 |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 VGX-3100, CELLECTRA™ 5PSP - Anal Neoplasm | Phase 2 | Completed | Inovio Pharmaceuticals | 23 | 2018-05-15 | 2023-07-14 |
| A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand BARRX™ Anorectal Wand - HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer | Phase 2 | Unknown | Stephen E. Goldstone | 70 | 2017-10-01 | 2017-10-05 |
| Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) Aminolaevulinic acid, Placebo - Cervical Intraepithelial Neoplasia, Low-Grade Squamous Intraepithelial Lesions | Phase 2 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 60 | 2016-03-22 | 2019-07-08 |
| A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions PepCan, Candin® - Cervical Intraepithelial Neoplasia | Phase 2 | Completed | University of Arkansas | 81 | 2015-11-30 | 2023-12-18 |
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions. Cidofovir - High Grade Cervical Epithelial Neoplasia (CIN2+) | Phase 2 | Completed | Brugmann University Hospital | 36 | 2013-02-01 | 2016-11-30 |
| Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection Gardasil - Infection, Precancerous Condition | Phase 2 | Completed | AIDS Malignancy Consortium | 112 | 2007-11-01 | 2023-11-14 |
| A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) A-007 - Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia | Phase 2 | Completed | Tigris Pharmaceuticals | 11 | 2007-11-01 | 2009-05-22 |
Showing 20 of 26. Sign in to see all of them.
Uterine Cervical Dysplasia (10) · Papillomavirus Infections (6) · Atypical Squamous Cells of the Cervix (4) · Anus Neoplasms (3) · Precancerous Conditions (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Squamous Cell (2) · Infections (2) · Skin Neoplasms (2) · HIV Seropositivity (1) · Squamous Intraepithelial Lesions of the Cervix (1)
Morphological and Microscopic Findings (26) · Pathological Conditions, Signs and Symptoms (26) · Neoplasms (18) · Genital Diseases (15) · Urogenital Diseases (15) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases, Female (13) · Uterine Cervical Diseases (13) · Uterine Diseases (13) · Precancerous Conditions (11) · Neoplasms by Site (8) · Communicable Diseases (7) · Sexually Transmitted Diseases (7) · Sexually Transmitted Diseases, Viral (7)
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (2) · Aminolevulinic Acid (2) · Biopsy (2) · Cidofovir (2) · VGX-3100 (2) · 5-aminolaevulinic acid-n-pentylester (1) · Acetic Acid (1) · Adjuvants, Pharmaceutic (1) · Antigens (1) · Biological Therapy (1) · Blue Light (1) · Celecoxib (1) · Chemoprevention (1) · DNA Methylation (1) · Electroporation (1)
AIDS Malignancy Consortium (3) · Newish Biotech (Wuxi) Co., Ltd. (2) · The Center for Clinical and Cosmetic Research (2) · Tigris Pharmaceuticals (2) · Amplexd Therapeutics, Inc. (1) · Boston University (1) · Brugmann University Hospital (1) · Department of Medical Services Ministry of Public Health of Thailand (1) · Gynecologic Oncology Group (1) · Inovio Pharmaceuticals (1) · Institut d'Investigació Biomèdica de Bellvitge (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1) · Sirnaomics (1)
United States (17) · China (4) · Puerto Rico (2) · Belgium (1) · Canada (1) · Hong Kong (1) · Sierra Leone (1) · Thailand (1)
Joel Palefsky, MD (3) · Cynthia J Goldberg, MD (2) · Keith A Aqua, MD (2) · Mark H Einstein, MD (2) · Mark S Nestor, MD, PhD (2) · Robert Pfeffer, MD (2) · Allan T Sawyer, MD (1) · Ana Eduardo, MD (1) · Beihua Kong, MD (1) · Bilal Fawaz, MD (1) · Brenda LaTowsky, MD (1) · Brian Jiang, MD (1) · Catherine Vanpachterbeke, MD (1) · Chandrika J. Piyathilake, PhD, MPH (1)
PMID 20812850, PMID 23032420, PMID 34907980
U01CA121947 (2), U10CA037429 (1), U10CA101165 (1), U24CA275417 (1), UM1CA121947 (1)